EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An mRNA-encoded bispecific T-cell engager targeting muscle-specific tyrosine kinase for myasthenia gravis

Yan Huang, Jia Zhang, Hongxiaoying Yu, Jianqi Zhang, Yongchao Zhao, Dong Xu, Ya Zhou, Fangling Zhang, Shanshan Zhou, Lun Zhang, Wei Xu, Xiaoyun Ma

Pharmacological Research · 2026-12 · 234 · 109733

DOI: 10.1016/j.phrs.2026.109733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2026-12. Verfasst von Yan Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: METiS TechBio, Beijing, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG) is a severe autoimmune disease with limited effective treatment options. We designed an mRNA-encoded bispecific T-cell engager (MuSK×CD3 TCE) comprising the human MuSK extracellular domain and an anti-CD3 single-chain variable fragment (scFv), delivered via a lipid nanoparticles (LNPs) to the liver to enable in vivo protein synthesis, which redirects cytotoxic T cells to eliminate B cells expressing anti-MuSK B cell receptors (BCR). In vitro, the MuSK×CD3 TCE mediated dose-dependent cytotoxicity against MuSK+ target cells and induced robust T cell activation. In human PBMC-engrafted NOG mice, mRNA-LNP administration led to dose-dependent and specific inhibition of tumor growth in anti-MuSK BCR-positive tumors, with no significant impact on non-target B cells. Importantly, the TCE retained potent cytotoxic activity in the presence of physiological concentrations of MuSK autoantibodies-a key consideration for clinical translation, as patients with MuSK-MG typically harbor circulating autoantibodies. This "off-the-shelf" mRNA-LNP platform offers a precise, controllable and potent immunotherapy strategy for MuSK-MG and may be broadly applicable for other autoantibody-mediated diseases to eliminate pathogenic BCR+ B cells.

Autor:innen und Institutionen

  • METiS TechBio, Beijing, China.
  • METiS TechBio, Hangzhou, China.
  • METiS TechBio, Beijing, China; METiS TechBio, Hangzhou, China. Electronic address: wei.xu@metistechbio.com.
  • METiS TechBio, Beijing, China. Electronic address: xyma@metistechbio.com.

Zitieren

APA

Huang, Y., Zhang, J., Yu, H., Zhang, J., Zhao, Y., Xu, D., Zhou, Y., Zhang, F., Zhou, S., Zhang, L., Xu, W., & Ma, X. (2026). An mRNA-encoded bispecific T-cell engager targeting muscle-specific tyrosine kinase for myasthenia gravis. Pharmacological Research, 234, 109733. https://doi.org/10.1016/j.phrs.2026.109733

Vancouver

Huang Y, Zhang J, Yu H, Zhang J, Zhao Y, Xu D, et al. An mRNA-encoded bispecific T-cell engager targeting muscle-specific tyrosine kinase for myasthenia gravis. Pharmacological Research. 2026;234:109733. doi:10.1016/j.phrs.2026.109733

BibTeX
@article{Huang2026,
  author = {Huang, Yan and Zhang, Jia and Yu, Hongxiaoying and Zhang, Jianqi and Zhao, Yongchao and Xu, Dong and Zhou, Ya and Zhang, Fangling and Zhou, Shanshan and Zhang, Lun and Xu, Wei and Ma, Xiaoyun},
  title = {An mRNA-encoded bispecific T-cell engager targeting muscle-specific tyrosine kinase for myasthenia gravis},
  journal = {Pharmacological Research},
  year = {2026},
  volume = {234},
  pages = {109733},
  doi = {10.1016/j.phrs.2026.109733}
}
Kostenlos starten →